Sign In
Buy DSNKY
$16.12
-1.81 (-10.09%)
At Close: Jul 31, 2026
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
07:00pm, Thursday, 19'th Feb 2026
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effectiv
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Daiichi Sankyo (TSE: 4568). T
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
07:00am, Wednesday, 04'th Feb 2026
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--The first patient has been dosed in a first-in-human phase 1/2 trial evaluating DS3790 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call Transcript
04:42am, Friday, 30'th Jan 2026
Daiichi Sankyo Company, Limited (DSNKY) Q3 2026 Earnings Call Transcript
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
01:30am, Thursday, 22'nd Jan 2026
TOKYO & MUNICH--(BUSINESS WIRE)--Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe. Dr. Jürg
Daiichi Sankyo Unveils New Toronto Headquarters to Accelerate Investment and Innovation in Oncology
08:00am, Wednesday, 21'st Jan 2026
Investment in Canadian headquarters fuels expansion of Canadian operations, advancing access to innovative cancer medicines TORONTO, Jan. 21, 2026 /PRNewswire/ - Daiichi Sankyo (TSE: 4568) has further
Daiichi Sankyo Company, Limited (DSNKY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
08:45pm, Monday, 12'th Jan 2026
Daiichi Sankyo Company, Limited (DSNKY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth
05:47am, Monday, 12'th Jan 2026
Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.
CPRX or DSNKY: Which Is the Better Value Stock Right Now?
12:40pm, Friday, 09'th Jan 2026
Investors looking for stocks in the Medical - Drugs sector might want to consider either Catalyst Pharmaceutical (CPRX) or Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway
01:30am, Thursday, 08'th Jan 2026
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio.
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe
02:30am, Wednesday, 07'th Jan 2026
MUNICH--(BUSINESS WIRE)--Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe.
Financial Comparison: Daiichi Sankyo (OTCMKTS:DSNKY) vs. Sandoz Group (OTCMKTS:SDZNY)
02:00am, Wednesday, 07'th Jan 2026
Sandoz Group (OTCMKTS:SDZNY - Get Free Report) and Daiichi Sankyo (OTCMKTS:DSNKY - Get Free Report) are both large-cap medical companies, but which is the better business? We will contrast the two com
Daiichi Sankyo (OTCMKTS:DSNKY) Shares Up 2.7% – Here’s Why
02:35am, Sunday, 28'th Dec 2025
Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) shares shot up 2.7% on Friday. The company traded as high as $21.99 and last traded at $21.99. 5,281 shares changed hands dur
CPRX vs. DSNKY: Which Stock Is the Better Value Option?
12:41pm, Wednesday, 17'th Dec 2025
Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Daiichi Sankyo Co., Ltd. - Sponsored ADR (DSNKY).
Daiichi Sankyo Company, Limited (DSNKY) Discusses Oncology Pipeline Advances and Phase III Clinical Updates at Science and Technology Day Transcript
